This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	Proteasome	<p><i>In vitro</i> and mouse studies identified a homopiperazine proteasome inhibitor that could help treat drug-resistant MM. In cultured, bortezomib-resistant MM cell lines and in mouse xenograft models of MM, the proteasome inhibitor blocked proliferation and decreased tumor volume compared with vehicle. Next steps include testing the molecule in additional mouse models of cancer.</p> <p>Takeda Pharmaceutical Co. Ltd. and Johnson & Johnson market the proteasome inhibitor Velcade bortezomib to treat MM and mantle cell lymphoma (MCL).</p> <p>Onyx Pharmaceuticals Inc. and Ono Pharmaceutical Co. Ltd. market the proteasome inhibitor Kyprolis carfilzomib to treat MM.</p> <p>SciBX 6(33); doi:10.1038/scibx.2013.889 Published online Aug. 29, 2013</p>	Patent and licensing status unavailable	<p>Kikuchi, J. <i>et al. J. Biol. Chem.</i>; published online July 22, 2013; doi:10.1074/jbc.M113.480574</p> <p>Contact: Yusuke Furukawa, Jichi Medical University, Tochigi, Japan e-mail: furuyu@jichi.ac.jp</p>